🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06088134
Recruiting Observational

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)

NCT06088134 · tracked via the Priya Life Science China tracker
Sponsor
Mingzhao Xiao
Phase
Observational
Started
2022-09-01
Last updated
2025-05-31

Condition(s) studied

Clear Cell Renal Cell CarcinomaPrognostic Cancer ModelRecurrent Renal Cell Cancer

Study summary

This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * underwent partial/radical nephrectomies * histologically diagnosed as ccRCC * with complete clinical data and preoperative CT image data Exclusion Criteria: * with incomplete clinic-pathological data * lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis * who received pre-surgery neoadjuvant or adjuvant therapies * with multiple renal tumors or/and had synchronous metastasis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yingjie Xv Chongqing Chongqing Municipality Recruiting

More Mingzhao Xiao trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06088134 on ClinicalTrials.gov ↗ ← All trials in China